We're using ML to develop a blood-based screening test for colorectal cancer, the second-most-deadly cancer (after lung). Over 50,000 people die every year in the US from this, because they don't find out they have it until too late.
https://techcrunch.com/2019/07/24/with-160-million-in-new-fu... https://bmccancer.biomedcentral.com/articles/10.1186/s12885-...
Unlike drugs, diagnostics require only a single large FDA study, which is starting now. We closed a $165M series B to pay for that. That included return participation from A16z and GV, along with Roche, Kaiser, and the American Cancer Society. The office is onsite at Verily and includes Alphabet amenities.
I manage the infrastructure engineering team, but we're hiring for a number of roles, many of which do not require any bio background. Check out https://www.freenome.com/careers or email me directly at michael.shields@freenome.com.